サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1318010

糖尿病治療薬市場：薬物タイプ別（注射薬、経口薬）、用途別（1型糖尿病、2型糖尿病）-2023～2030年の世界予測

Diabetes Drugs Market by Drug Type (Injectable Drug, Oral Drug), Application (Type 1 Diabetes, Type 2 Diabetes) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
糖尿病治療薬市場：薬物タイプ別（注射薬、経口薬）、用途別（1型糖尿病、2型糖尿病）-2023～2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病治療薬の世界市場は、2023年にCAGR 6.97%で631億1,000万米ドルと予測され、2030年には1,013億2,000万米ドルと驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の糖尿病治療薬市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.糖尿病治療薬の世界市場規模および予測は？

2.予測期間中、世界の糖尿病治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.糖尿病治療薬の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.糖尿病治療薬の世界市場における競争戦略は？

5.糖尿病治療薬の世界市場における技術動向と規制の枠組みは？

6.糖尿病治療薬の世界市場における主要ベンダーの市場シェアは？

7.糖尿病治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 糖尿病の有病率の増加
      • 不健康な食事と座りっぱなしのライフスタイルに伴う肥満の増加
      • 健康意識を高めるプログラムの数が急増
    • 抑制要因
      • 場合によっては薬の副作用
    • 機会
      • 製薬メーカーによる糖尿病治療薬の進歩
      • ヘルスケアへの投資とヘルスケアインフラの開発の増加
    • 課題
      • 薬の入手可能性に対する患者の意識の欠如
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 糖尿病治療薬市場：薬物タイプ別

  • イントロダクション
  • 注射薬
    • アスパルト
    • エクセナチド
    • グラルギン
    • インスリン
    • レラグルチド
    • プラムリンチド
  • 経口薬
    • α-グルコシダーゼ阻害剤
    • ビグアニデス
    • DPP-4阻害剤
    • メグリチニドおよびD-フェニルアラニン誘導体
    • スルホニル尿素
    • チアゾリジンジオン

第7章 糖尿病治療薬市場：用途別

  • イントロダクション
  • 1型糖尿病
  • 2型糖尿病

第8章 南北アメリカの糖尿病治療薬市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の糖尿病治療薬市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの糖尿病治療薬市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETES DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 5. DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. DIABETES DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. DIABETES DRUGS MARKET DYNAMICS
  • FIGURE 8. DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 14. DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES & D-PHENYLALANINE DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 193. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 194. DIABETES DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-434CCDA051CA

The Global Diabetes Drugs Market is forecasted to grow significantly, with a projected USD 63.11 billion in 2023 at a CAGR of 6.97% and expected to reach a staggering USD 101.32 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Diabetes Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Diabetes Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Injectable Drug and Oral Drug. The Injectable Drug is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral Drug is further studied across Alpha-Glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides & D-Phenylalanine Derivatives, Sulfonylureas, and Thiazolidinediones. The Oral Drug is projected to witness significant market share during forecast period.

Based on Application, market is studied across Type 1 Diabetes and Type 2 Diabetes. The Type 2 Diabetes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Diabetes Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetes Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetes Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetes Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Diabetes Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Diabetes Drugs Market?

6. What is the market share of the leading vendors in the Global Diabetes Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Diabetes Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Diabetes Drugs Market, by Drug Type, 2022 vs 2030
  • 4.3. Diabetes Drugs Market, by Application, 2022 vs 2030
  • 4.4. Diabetes Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of diabetes disease
      • 5.1.1.2. Rise in obesity coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.3. Surge in the number of programs to create health awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects of drugs in certain cases
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
      • 5.1.3.2. Rising investment in healthcare and development of healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness among patients towards the availability of drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Diabetes Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Injectable Drug
    • 6.2.1. Aspart
    • 6.2.2. Exenatide
    • 6.2.3. Glargine
    • 6.2.4. Insulin
    • 6.2.5. Leraglutide
    • 6.2.6. Pramlintide
  • 6.3. Oral Drug
    • 6.3.1. Alpha-Glucosidase Inhibitors
    • 6.3.2. Biguanides
    • 6.3.3. DPP-4 Inhibitors
    • 6.3.4. Meglitinides & D-Phenylalanine Derivatives
    • 6.3.5. Sulfonylureas
    • 6.3.6. Thiazolidinediones

7. Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Type 1 Diabetes
  • 7.3. Type 2 Diabetes

8. Americas Diabetes Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing